This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 32 open trials.
In 128 locations
What is a Clinical Trial?
There are currently 32 open trials
- Daratumumab with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients
- Venetoclax in combination with pomalidomide and dexamethasone in patients with relapsed or refractory myeloma
- Venetoclax and dexamethasone in patients with relapsed or refractory multiple myeloma
- Daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed AL amyloidosis
- Trial of immunomodulatory therapy in high risk solitary bone plasmacytoma (IDRIS)
- Effects of an exercise programme on smouldering myeloma and MGUS
- Selinexor with cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma patients (MUK twelve)
- Tanezumab for bone pain in myeloma
- Donor lymphocyte infusion after stem cell transplant in myeloma (ProT4).
- CC-92480 in combination with dexamethasone in relapsed and refractory multiple myeloma
- GMI-1271 with standard of care for the treatment of multiple myeloma
- Post authorisation study of Pomalidomide (Imnovid)
- GSK2857916 in patients who have failed prior treatment with an anti-CD38 antibody (DREAMM 2)
- MGUS research study
- AZD4573 in relapsed or refractory myeloma
- Daratumumab vs. monitoring in high risk smouldering myeloma
- Selinexor for relapsed and refractory myeloma (BOSTON)
- RO6870810 monotherapy and combination for relapsed and refractory myeloma patients
- Ixazomib, pomalidomide and dexamethasone for relapsed and/or refractory myeloma patients
- Targeted radiotherapy for myeloma
- Observational study of presentation, treatment and outcomes in myeloma patients (INSIGHT-MM)
- Observational evaluation of myeloma patients (PREAMBLE)
- Image guided theranostics in myeloma (iTIMM)
- MUK nine b: OPTIMUM
- CAR-T cell therapy for relapsed and/or refractory myeloma (APRIL)
- Melflufen and dexamethasone in myleoma patients refractory to lenalidomide (OCEAN trial)
- CC-220 monotherapy and combination for relapsed and refractory myeloma patients
- Myeloma XII (ACCoRd)
- Ixazomib and dexamethasone for relapsed or refractory AL amyloidosis patients
- Carfilzomib for newly diagnosed patients prior to stem cell transplant (CARDAMON trial)
- Bendamustine combination for newly diagnosed myeloma patients with kidney impairment (OPTIMAL trial)
- GSK525762 trial
Trial Title:
Daratumumab with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients
Treatments:
Daratumumab (Darzalex®)
Bortezomib (Velcade®)
Lenalidomide (Revlimid)
Dexamethasone
Myeloma stage:
Newly Diagnosed
Trial phase:
III
Summary:
This trial is determining whether daratumumab plus bortezomib, lenalidomide and dexamethasone is more effective than bortezomib, lenalidomide and dexamethasone alone for the treatment of newly diagnosed myeloma patients not receiving high-dose therapy and stem cell transplant (HD-SCT).
The trial hopes to show D-VRd improves overall minimal residual disease (MRD) negativity rate compared with VRd alone.
Locations:
North Manchester General Hospital, Manchester
Who can enter the study?:
Newly diagnosed myeloma patients not receiving HD-SCT as initial treatment.
What's involved?:
Patients will be randomised to receive either daratumumab plus bortezomib, lenalidomide (D-VRd) and dexamethasone or bortezomib, lenalidomide and dexamethasone (VRd).
For patients assigned to VRd:
- Bortezomib, lenalidomide and dexamethasone will be given in 21 day cycles for the first 8 cycles. Followed by lenalidomide and dexamethasone in 28 cycles until disease progression or treatment is stopped for other reasons.
- Bortezomib will be given subcutaneously (injection under the skin), lenalidomide and dexamethasone will be given orally.
For patients assigned to D-VRd:
- Daratumumab, bortezomib, lenalidomide and dexamethasone will be given in 21 day cycles for the first 8 cycles. Followed by daratumumab, lenalidomide and dexamethasone in 28 cycles until disease progression or treatment is stopped for other reasons.
- Daratumumab and bortezomib will be given subcutaneously (injection under the skin), lenalidomide and dexamethasone will be given orally.
Patients are required to attend outpatient clinics for regular check-ups and tests. Test will include bone marrow biopsies, blood tests, skeletal surveys and electrocardiograms (EGC).
Duration of the trial is approximately 6.5 years.
Clinical Information
(for Medical Professionals):
This trial is evaluating the safety and efficacy of daratumumab plus bortezomib, lenalidomide and dexamethasone is more effective than bortezomib, lenalidomide and dexamethasone alone for the treatment of newly diagnosed myeloma patients for whom HD-SCT is not planned as initial therapy.
The trial hopes to demonstrate that D-VRd improves overall MRD negativity rate compared with VRd alone. It will also evaluate PFS, OS, durable MRD negative rates, response duration and response rates.
For more information, click here.
Find out more: